Fund Overview of Tata India Pharma & Healthcare Fund Direct-growth
-
₹1,339.0 CrAUM
-
₹35.42NAV
-
0.61%Expense Ratio
-
EquityFund Category
Returns of Tata India Pharma & Healthcare Fund Direct-growth
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 3.32% | NA | 6.12% |
| 6 Months | 14.02% | NA | 12.92% |
| 1 Year | -0.27% | -0.27% | 6.04% |
| 2 Years | 55.75% | 24.80% | 24.93% |
| 3 Years | 101.11% | 26.22% | 25.71% |
| 5 Years | 148.95% | 20.01% | 19.91% |
| 7 Years | 250.39% | 19.62% | NA |
Asset Allocation
equities
93.81%other assets or cash equivalents
6.19%Tata India Pharma & Healthcare Fund Direct-growth is one Equity mutual fund offered by Tata Mutual Fund. Launched on 28 Dec 2015, the fund aims Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India. It manages assets worth ₹1,339.0 crore as on Thu Jul 31, 2025. , with a 52-week NAV range between ₹30.72 and ₹36.92. The expense ratio stands at 0.61%. Fund Manager Manager EducationAbout Tata India Pharma & Healthcare Fund Direct-growth
The portfolio allocation consists of 93.81% in equities, 6.19% in other assets or cash equivalents. Managed by Rajat Srivastava, it has delivered a return of -0.27% in the last year, a total return since inception of 14.10%.
Key Metrics of Tata India Pharma & Healthcare Fund Direct-growth
-
Standard Deviation15.97%
-
Sharpe Ratio1.09%
-
Alpha0.79%
-
Beta0.98%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
Tata India Pharma & Healthcare Fund Regular-growth  |
₹1,339 | -1.01% | -0.31% | -2.45% | 21.59% | 16.66% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from Tata Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Tata India Pharma & Healthcare Fund Regular-growth
|
₹1,339 | -1.01% | -0.31% | 9.26% | -2.45% | 21.59% |
|
Tata India Pharma & Healthcare Fund Regular-idcw
|
₹1,339 | -1.01% | -0.31% | 9.26% | -2.45% | 21.59% |
|
Tata India Pharma & Healthcare Fund Direct-idcw
|
₹1,339 | -0.89% | 0.07% | 10.08% | -0.96% | 23.41% |
|
Tata Nifty Midsmall Healthcare Index Fund Regular - Growth
|
₹161 | -1.17% | -0.40% | 11.54% | 3.18% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct - Growth
|
₹161 | -1.12% | -0.25% | 11.88% | 3.83% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Regular - Idcw
|
₹161 | -1.17% | -0.40% | 11.54% | 3.18% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct - Idcw
|
₹161 | -1.12% | -0.25% | 11.88% | 3.83% | - |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Tax Information
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not included. If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 20%. Any cess/surcharge is not included in the 20%.
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund Regular-growth |
₹1,339 | ₹30.35 | 21.59% | 16.66% | - |
| Edelweiss Msci India Domestic & World Healthcare 45 Index Fund Direct - Growth |
₹166 | ₹20.70 | 19.25% | - | - |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.92% | ₹146.17 Cr |
| Cipla Ltd | Healthcare | 6.62% | ₹88.60 Cr |
| Apollo Hospitals Enterprise Ltd | Healthcare | 5.20% | ₹69.60 Cr |
| Lupin Ltd | Healthcare | 4.77% | ₹63.83 Cr |
| Repo | Unspecified | 4.56% | ₹61.10 Cr |
| Healthcare Global Enterprises Ltd | Healthcare | 4.38% | ₹58.63 Cr |
| Torrent Pharmaceuticals Ltd | Healthcare | 4.32% | ₹57.89 Cr |
| Aster Dm Healthcare Ltd | Healthcare | 4.32% | ₹57.89 Cr |
| Fortis Healthcare Ltd | Healthcare | 4.00% | ₹53.56 Cr |
| Alkem Laboratories Ltd | Healthcare | 4.00% | ₹53.55 Cr |
| Max Healthcare Institute Ltd | Healthcare | 3.80% | ₹50.83 Cr |
| Wockhardt Ltd | Healthcare | 3.42% | ₹45.83 Cr |
| Divi's Laboratories Ltd | Healthcare | 3.06% | ₹40.98 Cr |
| Dr. Lal Pathlabs Ltd | Healthcare | 2.87% | ₹38.48 Cr |
| Metropolis Healthcare Ltd | Healthcare | 2.71% | ₹36.24 Cr |
| Ajanta Pharma Ltd | Healthcare | 2.67% | ₹35.70 Cr |
| Ipca Laboratories Ltd | Healthcare | 2.59% | ₹34.63 Cr |
| Aurobindo Pharma Ltd | Healthcare | 2.23% | ₹29.84 Cr |
| Mankind Pharma Ltd. | Healthcare | 2.15% | ₹28.72 Cr |
| Rainbow Childrens Medicare Ltd | Healthcare | 2.10% | ₹28.17 Cr |
| Fdc Ltd | Healthcare | 2.04% | ₹27.37 Cr |
| Dr. Reddy's Laboratories Ltd | Healthcare | 2.01% | ₹26.87 Cr |
| Dr. Agarwal’s Health Care Ltd. | Healthcare | 1.88% | ₹25.12 Cr |
| Krishna Institute Of Medical Sciences Ltd | Healthcare | 1.84% | ₹24.60 Cr |
| Cash/net Current Assets | Unspecified | 1.63% | ₹22.13 Cr |
| Niva Bupa Health Insurance Company Ltd. | Financial | 1.63% | ₹21.89 Cr |
| Syngene International Ltd | Healthcare | 1.58% | ₹21.13 Cr |
| Indoco Remedies Ltd | Healthcare | 1.02% | ₹13.62 Cr |
| Akums Drugs And Pharmaceuticals Ltd. | Healthcare | 1.00% | ₹13.36 Cr |
| Zydus Lifesciences Ltd | Healthcare | 0.99% | ₹13.31 Cr |
| Medi Assist Healthcare Services Ltd. | Industrials | 0.97% | ₹13.05 Cr |
| Medplus Health Services Ltd | Healthcare | 0.83% | ₹11.06 Cr |
| Hikal Ltd | Healthcare | 0.76% | ₹10.22 Cr |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 0.53% | ₹7.11 Cr |
| Ami Organics Ltd | Healthcare | 0.46% | ₹6.11 Cr |
| Krsnaa Diagnostics Ltd | Healthcare | 0.09% | ₹1.20 Cr |
| Laxmi Dental Ltd. | Healthcare | 0.05% | ₹0.61 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund Regular-growth |
₹30.35 | 21.59% | 16.66% | 32.01 |
growth is based on 5Y returns of the funds
Tata India Pharma & Healthcare Fund Direct-growth
What is the current AUM of Tata India Pharma & Healthcare Fund Direct-growth?
As of Thu Jul 31, 2025, Tata India Pharma & Healthcare Fund Direct-growth manages assets worth ₹1,339.0 crore
How has Tata India Pharma & Healthcare Fund Direct-growth performed recently?
- 3 Months: 3.32%
- 6 Months: 14.02%
What is the long-term performance of Tata India Pharma & Healthcare Fund Direct-growth?
- 3 Years CAGR: 26.22%
- 5 Years CAGR: 20.01%
- Since Inception: 14.10%
What is the portfolio composition of Tata India Pharma & Healthcare Fund Direct-growth?
Equity: 93.81%, Others: 6.19%.
Who manages Tata India Pharma & Healthcare Fund Direct-growth?
Tata India Pharma & Healthcare Fund Direct-growth is managed by Rajat Srivastava from Tata Mutual Fund.
What is the market-cap allocation of Tata India Pharma & Healthcare Fund Direct-growth?
Large Cap: 46.73%, Mid Cap: 16.51%, Small Cap: 36.76%.
Which are the top companies Tata India Pharma & Healthcare Fund Direct-growth has invested in?
- Sun Pharmaceutical Industries Ltd – 10.92% of the fund's portfolio
- Cipla Ltd – 6.62% of the fund's portfolio
- Apollo Hospitals Enterprise Ltd – 5.20% of the fund's portfolio
- Lupin Ltd – 4.77% of the fund's portfolio
- Repo – 4.56% of the fund's portfolio
Which are the major sectors Tata India Pharma & Healthcare Fund Direct-growth focuses on?
- Healthcare – 91.21% of the fund's portfolio
- Unspecified – 6.19% of the fund's portfolio
- Financial – 1.63% of the fund's portfolio
- Industrials – 0.97% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
